Neuropathology of Drug Addictions and Substance Misuse Volume 3

<p>Part I. Principles of Addictions, Overviews, Detailed Processes and Mechanisms</p> <p>Section A. General Aspects</p> <p>Chapter 1. Drugs and the Human Envirome</p> <p>Chapter 2. Psychoactive Plants Used during Religious Rituals</p> <p>Chapter 3. Substance Use Disorders and Comorbid Mental Illness: A Focus on Epidemiological Data Regarding Mood and Anxiety Disorders</p> <p>Chapter 4. Mephedrone and Mephedrone-Based Cocktails: Market, Analysis, Mechanisms of Action, and Toxicity</p> <p>Chapter 5. Substance-Induced Psychosis: Conceptual and Diagnostic Challenges in Clinical Practice</p> <p>Chapter 6. Sleep and Drug Addiction</p> <p>Section B. Molecular and Cellular Aspects</p> <p>Chapter 7. Hypothalamic and Midbrain Cells, Tyrosine Hydroxylase, and Implications for Drug Addiction</p> <p>Chapter 8. Oxytocin: Providing New Avenues for Treating and Understanding Problematic Drug Use</p> <p>Chapter 9. Role of D2-like Heteroreceptor Complexes in the Effects of Cocaine, Morphine, and Hallucinogens</p> <p>Chapter 10. Glutamate Receptors and Drug Addiction</p> <p>Chapter 11. Effect of Interacting Nonsteroidal Anti-Inflammatory Agents (NSAIDs) and Opioids on Mood: Pharmacodynamic Considerations in Misuse and Abuse</p> <p>Chapter 12. A Mini-Review on Different Commonly Used Abusive Drugs and the Interactions of These Drugs and Chinese Herbs</p> <p>Chapter 13. Interaction of Drugs of Addiction with DNA</p> <p>Chapter 14. Drugs of Abuse and DNA Methylation in the Brain: Ethanol, Cocaine, Amphetamine–Methamphetamine, Heroin, Antidepressants, and Antipsychotics</p> <p>Chapter 15. Orexin/Hypocretin System and Drug Addiction</p> <p>Chapter 16. Reverse Translational Implications of Genome-Wide Association Studies for Addiction Genetics</p> <p>Chapter 17. Polymorphisms in the Delta Opioid Receptor Gene (OPRD1) and Drug Addiction: Candidate Genes, Transgenic Mouse Models, and Genome-Wide Association Studies</p> <p>Chapter 18. Drug Addictions and Genetics of the Dopamine Pathway</p> <p>Chapter 19. In Silico Chemogenomics Knowledgebase and Computational System Neuropharmacology Approach for Cannabinoid Drug Research</p> <p>Chapter 20. Cocaine- and Amphetamine-Regulated Transcript (CART) Peptide and Drug Addiction</p> <p>Section C. Structural and Functional Aspects</p> <p>Chapter 21. The Cerebellar Landscape of Drug Addiction</p> <p>Chapter 22. Movement Dysfunction as a Neuropathology of Illicit Stimulant Abuse</p> <p>Chapter 23. Left Hemispheric “Imbalance” in Drug Addiction</p> <p>Chapter 24. Co-occurence of Substance Use and Personality Disorders: Epidemiology, Etiopathogenesis, and Treatment</p> <p>Chapter 25. Neonatal Abstinence Syndrome: Pharmacological Aspects</p> <p>Chapter 26. Comorbidity between Substance Use Disorder and Severe Mental Illness: Dual Diagnosis</p> <p>Part II. Prescription Medications: Depressants</p> <p>Section A. General Aspects</p> <p>Chapter 27. Lormetazepam Addiction</p> <p>Chapter 28. Prescribing and Dispensing of Benzodiazepines: Implications for Dependence and Misuse</p> <p>Section B. Molecular and Cellular Aspects</p> <p>Chapter 29. Bidirectional Plasticity of Hippocampal Glutamate Receptors Is Central to Expression of Benzodiazepine Withdrawal-Anxiety</p> <p>Chapter 30. Effect of Chronic Benzodiazepine Exposure on GABAA Receptors: Regulation of GABA/Benzodiazepine Site Interactions</p> <p>Chapter 31. The K+-Cl− Cotransporter KCC2 and Zolpidem</p> <p>Section C. Structural and Functional Aspects</p> <p>Chapter 32. Benzodiazepine Misuse and Addiction. Risk Factors and Adverse Behavioral Aspects</p> <p>Chapter 33. Benzodiazepines, Age-Related Pharmacological Changes, and Risk of Falls in Older Adults</p> <p>Chapter 34. The Substantia Nigra Pars Reticulata in Sedative-Hypnotic Withdrawal</p> <p>Section D. Methods</p> <p>Chapter 35. Assays for Benzodiazepines</p> <p>Part III. Opioids and Morphine Derivatives</p> <p>Section A. General Aspects</p> <p>Chapter 36. Weak Opioid Analgesics Abuse and Addiction: A Comparison of the Pharmacology and Pharmacoepidemiology of Codeine, Dihydrocodeine, and Tramadol</p> <p>Chapter 37. Maternal Codeine and Its Effect on the Fetus and Neonate: A Focus on Pharmacogenomics, Neuropathology, and Withdrawal</p> <p>Chapter 38. Methadone Usage, Misuse, and Addiction Processes: An Overview</p> <p>Chapter 39. Tramadol, Usage, Misuse, and Addiction Processes</p> <p>Chapter 40. Tramadol Abuse in the Elderly</p> <p>Section B. Molecular and Cellular Aspects</p> <p>Chapter 41. Oligodendrocyte Responses, Myelination, and Opioid Addiction Treatments</p> <p>Chapter 42. Opioids and TRPV1 Receptors</p> <p>Chapter 43. Opioids and Serotonin Syndrome: An Example with Tramadol</p> <p>Chapter 44. Opioid Dependence and the Adenylyl Cyclase/cAMP Signaling</p> <p>Chapter 45. Central Nervous System Penetration of the Opioid Oxycodone</p> <p>Chapter 46. Opioid Modulation of Voltage-Gated Calcium Currents</p> <p>Chapter 47. The Neonatal Brain and Opioids</p> <p>Chapter 48. Contribution of Spinal Cord mTORC1 to Chronic Opioid Tolerance and Hyperalgesia</p> <p>Chapter 49. Interaction of Codeine with DNA</p> <p>Chapter 50. Fentanyl and Its Impact on Cell Functions</p> <p>Chapter 51. Morphine and Trafficking of a Mu Opioid Receptor Interacting Protein WLS</p> <p>Chapter 52. Fas, Bcl-2, and Caspase-3 Protein and Morphine Addiction</p> <p>Chapter 53. An Overview on Methadone-Intoxicated Patients</p> <p>Chapter 54. Genetic Polymorphisms on OPRM1 Involved in Multiple Responses of a Methadone Maintenance Population: Relationships with Insomnia, Libido, Smoking, and Chemokines</p> <p>Section C. Structural and Functional Aspects</p> <p>Chapter 55. Modulation of Opioid Analgesic Reward by Inflammatory Agents</p> <p>Chapter 56. Suicidal Behavior and Prescription Opioid Medication</p> <p>Chapter 57. Codeine and Psychomotor Activity</p> <p>Chapter 58. Neurobehavior of Neonates Born to Mothers Receiving Opioid Maintenance Treatment: Methadone and Buprenorphine</p> <p>Chapter 59. Prenatal Methadone and Behavioral Sensitization Induced by Methamphetamine</p> <p>Chapter 60. Treatments for Opioid Dependence and Methadone: Neurological and Behavioral Aspects</p> <p>Chapter 61. Cognitive Functioning in Methadone Use</p> <p>Chapter 62. Sleep Disturbances in Methadone Maintenance Treatment (MMT) Patients</p> <p>Section D. Methods</p> <p>Chapter 63. The Neuropathology of Drug Addictions and Substance Misuse: Assays for Fentanyl</p> <p>Chapter 64. Assays for Tramadol and Its Metabolites</p> <p>Part IV. Stimulants and Other Compounds</p> <p>Section A. General Aspects</p> <p>Chapter 65. Methylphenidate Abuse: An Overview</p> <p>Section B. Molecular and Cellular Aspects</p> <p>Chapter 66. The Impact of Methylphenidate on Circadian Rhythms and Clock Gene Expression</p> <p>Section C. Structural and Functional Aspects</p> <p>Chapter 67. The Characteristics of Acute and Chronic Methylphenidate, Dose, and Route on Female and Male Animal Behavior</p> <p>Chapter 68. Methylphenidate and Cognitive Performance</p> <p>Chapter 69. Methylphenidate and Suicide</p> <p>Chapter 70. The Effect of Methylphenidate on the Ventral Tegmental Area in Adolescent and Adult Animals</p> <p>Chapter 71. Dextromethorphan and Dextrorphan as Heuristic Rapid-Acting, Conventional, and Treatment-Resistant Antidepressants, with Substance Abuse Considerations</p> <p>Part V. Caffeine and Areca (Betal Nut)</p> <p>Section A. General Aspects</p> <p>Chapter 72. Caffeine and Taurine and Energy Drink Abuse</p> <p>Chapter 73. General Aspects of Areca Nut Addiction</p> <p>Section B. Molecular and Cellular Aspects</p> <p>Chapter 74. Caffeine, Adenosine A1 Receptors, and Brain Cortex. Molecular Aspects</p> <p>Chapter 75. Caffeine and the Developing Brain: Molecular and Cellular Effects</p> <p>Section C. Structural and Functional Aspects</p> <p>Chapter 76. Effects of Caffeine and Its Cortical Response Studied by Functional Brain Imaging</p> <p>Chapter 77. Neurobehavioral Aspects of Caffeine</p> <p>Chapter 78. Oral and Systemic Health Effects of Compulsive Areca Nut Use</p> <p>Chapter 79. Areca Alkaloids and Schizophrenia</p> <p>Chapter 80. Attentional Biases for Betel Nut Cues</p> <p>Section D. Methods</p> <p>Chapter 81. Quantitative Measurement of Caffeine by Optical Methods</p> <p>Chapter 82. Betel Quid Dependence Scale</p> <p>Part VI. Dual and Polydrug Abuse</p> <p>Chapter 83. Types of Polydrug Usage</p> <p>Chapter 84. Polypharmacy of Potentially Addictive Medications and the Elderly</p> <p>Chapter 85. New Insight into Alcohol and Nicotine Addiction: Neurobiological Findings and Therapeutical Perspectives</p> <p>Chapter 86. Multimodal Magnetic Resonance Neuroimaging and Cognition in Polysubstance Users</p> <p>Chapter 87. Neuropathological Studies in Polydrug Abusers</p> <p>Part VII. Emerging Addictions and Drugs of Abuse</p> <p>Chapter 88. Novel Drugs of Abuse: Cannabinoids, Stimulants, and Hallucinogens</p> <p>Chapter 89. Kratom (Mitragyna speciosa) Use, Addiction Potential, and Legal Status</p> <p>Chapter 90. Methylxanthines and Drug Dependence: Interactions and Toxicity</p> <p>Chapter 91. The Neuropathology of Movement Disorders in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and Methcathinone (Ephedrone) Addictions</p> <p>Chapter 92. 25C-NBOMe as a New Hallucinogen</p> <p>Chapter 93. Pregabalin Abuse and Addiction</p> <p>Part VIII. Non-Drug Addictions as Comparative Neuropathology</p> <p>Chapter 94. Internet Gaming Disorder</p> <p>Chapter 95. The Neuropathology of Internet Addiction</p> <p>Chapter 96. Workaholism: An Addiction to Work</p> <p>Chapter 97. Exercise Addiction</p> <p>Chapter 98. Compulsive Buying—Features and Characteristics of Addiction</p> <p>Chapter 99. Food Addiction: Applying Substance Use Disorder Criteria and Characteristics to Identify Instances of Addictive-Like Eating</p> <p>Chapter 100. Bulimia Nervosa as an Addiction</p> <p>Chapter 101. Gambling Disorders: A Focus on Genetic Aspects</p>